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INTRODUCTION
Lung cancer ranks among the most commonly occurring
malignancies and currently is the leading cause of cancer-relat-
ed deaths worldwide (1). It is also the most common origin
of brain metastases, accounting for 40-50% of such cases (2).
Patients with brain metastases who go untreated have a
median survival of 1 month and this can be prolonged for
about 1 month by treatment with corticosteroids. Radiother-
apy prolongs median survival to 3-8 months (3-5). Total exci-
sion of tumor combined with radiotherapy resulted in better
survival compared with radiotherapy alone (6-8). Recently,
stereotactic radiosurgery became a widely used treatment
modality, achieving effective local control of brain metastases
(9). Radiosurgery is a noninvasive alternative to surgical exci-
sion and very useful for multiple or deep-seated lesions which
cannot be managed with surgery. The survival of cancer pa-
tients with brain metastases who are treated with radiosurgery
is mainly influenced by the progression of their primary site
tumor or extracranial metastases, rather than by the brain
lesions themselves (10). Because clinical pattern of disease
progression is different according to type of cancer, it is nec-
essary to investigate the clinical outcome of metastatic brain
tumors in each individual type of cancer. Synchronous brain
metastases accompany 7.4-10% of newly diagnosed non-small
cell lung cancer (NSCLC) (11, 12) and the probability of the
concurrent brain lesion at initial diagnosis of NSCLC is much
higher than other solid organ cancers. 
Optimal treatment strategy in this specific situation can
be established based on the outcome data also specific in the
situation. Although there have been numerous reports demon-
strating that stereotactic radiosurgery provides effective local
control of metastatic brain lesions, little is known about the
overall outcome of NSCLC with synchronous cerebral metas-
tases treated with radiosurgery. Therefore, we carried out a
retrospective study to determine the survival time and iden-
tify the prognostic factors for synchronous brain metastases
from NSCLC in which gamma knife radiosurgery (GKS) was
performed as an initial treatment. 
MATERIALS AND METHODS
In the period between May 2001 and October 2004, 35
patients with synchronous metastatic cerebral lesions from
NSCLC underwent GKS as a part of their initial treatment
(Table 1). There were 27 male (77.1%) and 8 female patients
(22.9%), with a mean age of 55.3 yr (range 33-81). We includ-
ed patients whose brain lesions were diagnosed before or with-
in 2 months from the diagnosis of the primary tumors. The
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Prognosis of Non-Small Cell Lung Cancer with Synchronous Brain
Metastases Treated with Gamma Knife Radiosurgery
The clinical outcome and prognostic factors of patients with synchronous brain meta-
stases from non-small cell lung cancer (NSCLC) who were treated with gamma knife
radiosurgery (GKS) were analyzed. A total of 35 patients with NSCLC underwent
GKS as an initial treatment for metastatic brain lesions of synchronous onset. The
period of survival and various prognostic factors such as age, gender, performance
status, multiplicity of the brain lesions, intracranial tumor volume, and extent of the
primary tumor were analyzed. The overall median survival time for this series was
12 months (range 0.75 to 43 months) from the diagnosis. Of the 21 patients who
were no longer alive at the conclusion of this study, only 7 (33.3%) died of neurologi-
cal causes. Multivariate analysis of these data revealed that N stage, whole-brain
radiotherapy (WBRT), and chemotherapy were significant predictors for survival
(p<0.05). Survival of patients with NSCLC and synchronous brain metastases is
mainly dependent upon the progression of the systemic disease, provided that the
cerebral lesions are treated adequately with local treatment modalities including radio-
surgery. Application of radiosurgery as an initial treatment option and aggressive local
and systemic modalities to control extracranial disease may improve survival.
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cytological or histological diagnosis of the primary site tumor
was carried out by means of open biopsy and/or resection, fine
needle aspiration biopsy, or bronchial lavage during broncho-
scopy. The histologic subtypes were adenocarcinoma in 29
patients, large cell carcinoma in 2, and unclassified in 4. In
terms of the extent of the disease excluding the brain lesions,
as measured by the international staging system (12), there
were 3 patients with stage I, 11 with stage II, 14 with stage
III, and 7 with stage IV. The patients’ general condition was
assessed using the Karnofsky performance status (KPS) score.
Thirty patients had a KPS score of 70 or more and five pa-
tients had a KPS score less than 70. All of the patients under-
went GKS as a part of their initial treatment using Leksell
model B and C gamma knife. A total of 166 brain lesions
were treated initially and the numbers of brain lesions were
one in 9 patients, 2 in 7 patients, 3 in 7 patients and more
than 3 in 12 patients. The mean number of lesions per patient
was 4.7 (range 1-27). The mean intracranial total tumor vol-
ume was 10.6 cm
3 (0.2-50.9 cm
3). The mean marginal dose
was 18.8 Gy (11-25 Gy) and the median marginal isodose
was 50% (36-75%) of the maximal dose. GKS was performed
in the several cases with extraordinary large volume or number
of lesions if they would have no available treatment options
in case of progression after WBRT only and their performance
status was favorable. Although dose planning was compro-
mised to acquire acceptable level of predictable complication,
it was assumed that even low dose of boost would provide
marginal benefit with acceptable risk and cost. GKS was per-
formed more than once in 11 patients with local recurrence
or the occurrence of new lesions during the follow up period.
Twenty seven patients received whole-brain radiotherapy
(WBRT) (a total dose of 3,000 cGy in 10 fractions) with inter-
val not longer than two weeks before or after GKS. Five pa-
tients underwent surgical excision of the primary site tumor.
Twenty patients were given systemic chemotherapy after GKS.
The mean 5 cycles of chemotherapy, consisting of taxotere/
cisplatinum, were given and second-line chemotherapy pro-
tocol consisting of gemcitabine or gefitinib (Iressa) was admi-
nistered additionally in 5 patients among them.
Survival curves were obtained by the Kaplan-Meier method
using a statistical software program (SPSS, Inc., Chicago, IL,
U.S.A.). Comparisons of survival from the univariate analysis
were conducted using the log-rank test, while the multivari-
ate analysis was conducted using the Cox proportional haz-
ards model. The results were considered significant when the
pvalue was less than 0.05. 
RESULTS
Survival time and causes of death
The mean follow up period was 12.5 months (0.75-43 mon-
ths) and, at the conclusion of the study, 21 patients had died
and 14 were still alive. The overall median survival time was
12 months (0.75-43 months) from the diagnosis of brain
metastasis. The survival rates were 47.7% at 1 yr and 32.5
% at 2 yr, as shown in Fig. 1. The causes of death were pro-
gression of the brain lesions in 7 patients (33.3%), progres-
sion of extracranial disease in 12 patients (57.2%), and un-
known origin in 2 patients (9.5%).
Local control, recurrence, development of new lesions
and complications after GKS
Local recurrence or development of new lesions in brain
occurred in 6 (17.1%) and 11 (31.4%) patients, respectively.
The actuarial rates without local recurrence were 93.1% at
6 months and 68.6% at 1 yr after the first GKS. Mean mar-
ginal dose and tumor volume in the patient with local recur-
rence were 18.8 Gy and 7.5 cm
3 each respectively. The actu-
arial rates without development of new lesions in the brain
were 86.9% at 6 months and 59.7% at 1 yr. Therefore, the
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Fig. 1. Overall survival time from the diagnosis of the brain metas-
tases in the 35 patients who underwent gamma knife surgery.
Characteristics No.
Sex Male 27
Female 8
Age (yr) <60 21
≥60 14
No. of lesions 1-3 23
≥41 2
Karnofsky performance score (KPS) <70 5
≥70 30
Whole brain radiotherapy (WBRT) 27
No WBRT 8
Chemotherapy 20
No chemotherapy 15
Presence of extracranial metastases 21
No extracranial metastasis 14
Table 1. Characteristics of 35 patients with synchronous brain
metastases from non-small cell lung cancer treated with gamma
knife radiosurgeryNSCLC with Synchronous Brain Metastases 529
survival rates without any progression of brain lesions were
80.3% at 6 months and 36.9% at 1 yr from the diagnosis.
Eleven patients (31.4%) needed second or more GKS up to
five times and the mean interval between the first and second
GKS was 8.3 months. Adverse effects of radiosurgery, most-
ly radiation necrosis, developed in 5 patients (14.3%) who
were treated with mean marginal doses of 18.8 Gy for mean
tumor volume of 6.0 cm
3. Major permanent disability occu-
rred in 1 patient (2.9%) who was treated with GKS twice for
the same lesion. Statistically significant relationship between
dose/volume and local control/toxicity could not be identified.
Prognostic factors for survival 
The results of the univariate analysis for those factors that
may influence survival are summarized in Table 2. Age, N
stage, KPS score, WBRT, and systemic chemotherapy were
found to affect survival. Age younger than 60 yr old, the
absence of regional lymph node involvement (N0) (Fig. 2),
WBRT (+) (Fig. 4), chemotherapy (+) (Fig. 3), and KPS score
70 or more were favorable factors for longer survival. Mean-
while, survival was not significantly influenced by sex, extra-
cranial metastasis, number of brain lesions (Fig. 5), intracra-
nial tumor volume, TNM stage and the histologic type. The
median survival time for patients with one to three lesions
was 12.2 months from the diagnosis of brain metastasis, while
that for patients with four or more lesions was 9.8 months.
However, the difference did not reach statistical significance
(p>0.05).
Multivariate analysis, designed to clarify the independent
role of those prognostic factors which were identified as hav-
ing a significant influence in the univariate analysis, revealed
that N stage, WBRT, and chemotherapy were significant pre-
dictors for survival (p<0.05) (Table 2). 
Months (time from brain metastases)
01 02 0 3 04 0 5 0
S
u
r
v
i
v
a
l
1.0
0.8
0.6
0.4
0.2
0
Fig. 5. Survival time according to the number of brain lesions. Sur-
vival tended to be shorter in patients with four or more lesions, but
the difference did not achieve statistical significance.
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Fig. 2. Survival time according to the N status of the primary lung
cancer. The survival time is significantly shorter in those patients
with a later N status.
N status: 0
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Fig. 3. Survival time according to the systemic chemotherapy. Pa-
tients who received chemotherapy show longer survival time sig-
nificantly than those who did not.
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Fig. 4. Survival time according to the whole brain radiotherapy.
Longer survival is shown in patients who underwent WBRT+GKS
than those who did GKS only.
GKS+WBRT
GKS only530 D.-S. Kong, J.-I. Lee, D.H. Nam, et al.
DISCUSSION
Recently, stereotactic radiosurgery has become a widely
used treatment modality for brain metastases. However, there
is still some controversy surrounding the proper indications
for radiosurgery, because improved local control of brain le-
sions does not guarantee the improved survival of patients
with a short life expectancy, due to the progression of extracra-
nial disease. The recently reported results of an randomized
trial of WBRT vs. WBRT and radiosurgery revealed that
radiosurgery provided a survival gain in recursive partition-
ing analysis (RPA) (14) class 1 patients of 25 months vs. 5
months (8, 15). This study was limited to patients with a
small number (1 to 3) of brain lesions, however, there have
been several reports which insisted that radiosurgery in pa-
tients with larger numbers of metastases is beneficial (16-19),
although they were not randomized trials. In this series, we
did not limit the number of brain lesions in the radiosurgi-
cal treatment. Predictably, those patients with one to three
lesions had a longer survival time than those with four or
more lesions (12.2 vs. 9.8 months), even if this difference was
not statistically significant probably due to the small num-
ber of patients in this study. However, the survival of both
groups in this series is still better than the comparable data
in the literature in which median survival was 3.6 months
with WBRT only (3, 5). At the same time, our results show
that the prognosis of patients with synchronous brain metas-
tases is not worse than those with metachronous lesions. A
similar result was reported by Flannery et al. (20). The major
cause of death in this series was the progression of systemic
disease (57.2%), regardless of the initial status of the brain
lesions (e.g. multiplicity or volume), and it is suggested that
effective local treatment modality for brain lesions could pre-
vent death from neurologic causes resulting in survival gain.
In this series, the prognostic factors identified by the mul-
tivariate analysis were N stage, WBRT, and chemotherapy.
N stage is a well known prognostic factor of NSCLC and our
results show that it is still significant in the patients with meta-
static bran lesions. Most of the patients in this study under-
went WBRT and survival was longer with GKS and WBRT
than GKS only. Recently there are several reports suggesting
that radiosurgery only may produce survival outcome com-
parable to radiosurgery plus WBRT in selected patients par-
ticularly with small number of lesions with controlled prima-
ry tumor (15, 19). Somewhat contradictory result of our study
may be caused by the different characteristics of the patients.
One third of the cases included in this study had more than
3 brain lesions and all had the primary tumor that was not
controlled at the time of GKS. It is thought that WBRT is
still an effective treatment option in the situation of synchro-
nous brain metastases. The better survival with systemic che-
motherapy can be interpreted in two ways. One may be that
it is a reflection of selection bias. Those patients with a bet-
ter general condition and a strong motivation to recover might
be preferentially selected for chemotherapy, thereby resulting
in their having a longer survival. The other, more optimistic
interpretation is that the delayed progression of the disease
resulted from the systemic chemotherapy. Systemic chemo-
therapy might influence not only the extracranial disease, but
also the brain lesions. However, it is not possible to draw
conclusions, because this study is not a randomized trial and
the number of patients included is too small. Whatever the
right interpretation is, it is clear that the adequate control
of brain lesions can prolong the patient’s survival, until death
occurs as a result of systemic disease. In other words, control
of the primary tumor is the most important for the further
prolongation of survival, if adequate local treatment (e.g. ra-
diosurgery with WBRT) has already been administered for
the brain lesions. 
Quality of life is an issue as important as survival and only
one randomized trial reported KPS outcomes for WBRT
alone vs. WBRT with radiosurgery boost (21). Concerning
the issue, our study has limitation as a retrospective study
mainly focused on survival outcome. However, most of the
patients died due to systemic causes rather than neurologi-
cal ones and it seems that major disabling symptoms in
these patients were not neurological problems. 
Our results have some practical implications in making
decision of treatment strategy when the patient was diagnosed
as having lung cancer with simultaneous brain lesions. If the
poor prognosis is expected due to the presence of brain lesions,
it is reasonable to withhold aggressive local or systemic treat-
ment to the primary site tumor or extracranial disease. Sever-
al previous studies reported improved survival with surgical
excision of both the primary tumor and intracranial lesions
(survival rate 56-66.4% at 1 yr), mostly in case of a few metas-
tases in brain and resectable lung lesion (10, 22, 23). It is tho-
ught that a similar principle may be applied when the use
of radiosurgery and chemotherapy is considered for patients
with multiple brain lesions and advanced extracranial disease.
Because the treatment of brain lesions with radiosurgery can
afford a substantial period of freedom from disease progres-
Variables
Univariate analysis Multivariate analysis
(p value) (p value)
Sex NS -
Age (<60 vs. >60 yr) 0.0063 NS*
KPS score (≥70 vs. <70) 0.0177 NS
N stage (N0 vs. N1-3) 0.0206 0.015
GKS with WBRT vs. GKS only 0.0050 0.018
Systemic chemotherapy 0.0349 0.025
No. of brain lesion (1-3 vs. ≥4) NS -
Extracranial metastasis NS -
TNM stage (excluding brain lesions) NS -
Histologic type NS -
Table 2. Uni- and multi-variate analysis of 35 patients with non-
small cell lung cancer with synchronous brain metastasis treat-
ed by gamma knife surgery
*NS, not significant.sion in the brain, trial of aggressive treatment to extracranial
disease may improve survival. Currently, the response rate of
advanced stage NSCLC to chemotherapy is known to be in
the range of 42-60%, depending on the regimen (24, 25). It
means that at least a subgroup of patients may benefit from
the aggressive treatment of their brain lesions followed by
systemic chemotherapy. Recently it was reported that medi-
an survival was longer with WBRT and chemotherapy for
NSCLC with synchronous brain metastases (58.1 weeks) than
WBRT and best supportive care only (19.0 weeks) (26). This
data support benefit of chemotherapy. In this study, the main
cause of chemotherapeutic failure was extracranial progression,
however, still there was aggravation of neurologic status in
19.6%. It suggests that effectively combined local and sys-
temic modality may further improve the outcome. This issue
needs to be further investigated through randomized trial and
quality of life as well as survival would be another important
point of consideration. 
In conclusion, radiosurgery should be considered as a part
of initial treatment in NSCLC patients with metastatic brain
lesions of synchronous onset. Systemic treatment following
the aggressive local treatment of brain lesions may provide
further survival gain. 
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